Drugs / JNJ-64417184
Trials 8
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT04453189 | Jul → Sep 2020 | — | Janssen Research & Development, LLC | Completed | No outcome recorded |
| Phase 1 | NCT04426357 | Jul → Nov 2020 | impaired renal function disease | Janssen Pharmaceutica N.V., Belgium | Terminated | No outcome recorded |
| Phase 1 | NCT04258189 | Feb → Aug 2020 | — | Janssen Research & Development, LLC | Completed | No outcome recorded |
| Phase 1 | NCT04208373 | Dec 2019 → Mar 2020 | — | Janssen Research & Development, LLC | Completed | No outcome recorded |
| Phase 1 | NCT04121052 | Oct → Dec 2019 | — | Janssen Research & Development, LLC | Completed | No outcome recorded |
| Phase 1 | NCT04090086 | Sep → Dec 2019 | — | Janssen Research & Development, LLC | Completed | No outcome recorded |
| Phase 1 | NCT03952507 | May → Jun 2019 | — | Janssen Research & Development, LLC | Completed | No outcome recorded |
| Phase 1 | NCT03403348 | May 2018 → Nov 2019 | — | Janssen BioPharma, Inc. | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 8 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | JNJ-64417184 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04453189 ↗ |
| Route | Oral | “single and multiple oral doses of JNJ-64417184” NCT03403348 ↗ |